- Home
- SHLS vs FTRE Comparison
SHLS vs FTRE Comparison
Compare SHLS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | FTRE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SHLS | FTRE |
|---|---|---|
| Price | $8.71 | $19.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $9.07 | ★ $14.06 |
| AVG Volume (30 Days) | ★ 6.0M | 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $475,331,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $26.24 | N/A |
| Revenue Next Year | $11.52 | $3.09 |
| P/E Ratio | $122.29 | ★ N/A |
| Revenue Growth | ★ 19.07 | 1.00 |
| 52 Week Low | $4.45 | $7.22 |
| 52 Week High | $13.18 | $21.39 |
Technical Indicators
Market Signals| Indicator | SHLS | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 55.61 |
| Support Level | $7.61 | $15.69 |
| Resistance Level | $9.91 | $21.39 |
| Average True Range (ATR) | 0.70 | 1.32 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 28.03 | 41.99 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.